**Current Status and Limitations of Androgenetic Alopecia (AGA)**
Androgenetic alopecia (AGA) is the most common progressive form of hair loss. Its core mechanism involves genetically susceptible hair follicles becoming overly sensitive to androgens (especially dihydrotestosterone, DHT), leading to follicular miniaturization and shortened anagen phase. Currently, the FDA-approved oral finasteride (a 5α-reductase inhibitor) and topical minoxidil (a potassium channel opener) represent the standard first-line treatments. However, approximately 20–30% of patients discontinue therapy due to insufficient efficacy or side effects (e.g., sexual dysfunction with finasteride). Consequently, scientists are exploring multiple new targets to develop more effective and safer drugs.
**Targeting the Androgen Signaling Pathway: From Antagonism to Degradation**
Next-generation androgen receptor (AR) antagonists are a major research focus. For example, the topical AR antagonist clascoterone (CB-03-01) has been approved for acne and has shown potential for promoting hair growth in phase II clinical trials for AGA—it directly and competitively inhibits DHT binding to the AR, avoiding the systemic side effects associated with oral administration. Another direction involves selective androgen receptor degraders (SARDs), such as GT-20029, which are designed to induce AR protein degradation and block signaling at its source. These drugs are currently in early clinical stages, with no large-scale phase III data yet available.
**Prostaglandin Analogs: Inspiration from Eyelash Lengthening**
Latanoprost, originally developed for glaucoma, gained attention due to its common side effect of “longer, thicker eyelashes.” Its mechanism involves activating the Wnt/β-catenin pathway via the prostaglandin FP receptor, thereby prolonging the anagen phase of hair follicles. Phase II trials for AGA have shown that topical latanoprost can increase vertex hair density, but its effect is weaker than minoxidil, and some patients experience ocular irritation. Another analog, bimatoprost, has been approved for eyelash hypotrichosis, but progress in developing it for AGA has been relatively slow.
**Wnt/β-catenin Signaling Pathway: A Central Hub for Hair Follicle Regeneration**
The Wnt pathway is a key regulator of hair follicle development and regeneration. The early drug SM04554 (a Wnt/β-catenin agonist) showed increased hair counts in phase II trials, but development was later terminated due to insufficient efficacy. Currently, more attention is being given to exogenous Wnt agonists (e.g., Wnt3a protein or small-molecule mimetics) and to activating the pathway by inhibiting negative Wnt regulators (e.g., SFRP1). However, these drugs face challenges related to target specificity: excessive Wnt activation may increase the risk of tumors, resulting in a narrow therapeutic window.
**JAK Inhibitors: Cross-Exploration from Alopecia Areata to AGA**
The role of the JAK-STAT pathway in alopecia areata (an autoimmune form of hair loss) has been confirmed, and JAK inhibitors such as baricitinib have been approved for severe alopecia areata. However, in AGA, inflammation is not a core mechanism, so the theoretical rationale for JAK inhibitors is weaker. Several small clinical studies have examined the effects of oral tofacitinib and topical JAK inhibitors (e.g., ATI-50002) on AGA, yielding conflicting results with small sample sizes. The prevailing view is that evidence for the benefit of JAK inhibitors in AGA is insufficient, and they are not recommended for routine treatment.
**Stem Cells and Exosomes: A Glimmer of Regenerative Medicine?**
Senescence of hair follicle stem cells (HFSCs) is believed to underlie the progression of AGA. Researchers have attempted local transplantation of autologous adipose-derived stem cells (ADSCs) or hair follicle-derived stem cells, but challenges remain, including low survival rates and poor engraftment. In recent years, exosomes—nanoscale vesicles secreted by cells—have become a new focus due to their abundance of growth factors (e.g., VEGF, IGF-1). Small-scale human studies have shown that exosome injections can improve hair growth cycles, but all lack randomized controlled evidence. Moreover, issues regarding source, dosage, and batch consistency have yet to be standardized, making clinical application a distant prospect.
**Gene Therapy and RNA-Based Therapies: A Vision for Precision Intervention**
Given the polygenic nature of AGA, gene therapy remains at a conceptual stage. One approach involves the local delivery of plasmid DNA or mRNA encoding growth factors (e.g., FGF-7) to transiently “reprogram” hair follicles. However, hair follicles in balding areas are already miniaturized, and gene delivery efficiency is low, with potential risks of immunogenicity. Small interfering RNA (siRNA) technology can silence androgen receptor gene expression, and animal studies have shown it can inhibit follicular miniaturization—yet delivery systems and off-target effects remain obstacles. These technologies are expected to enter clinical use within 10–20 years but cannot replace current therapies in the near term.
**Improvements to Existing Drugs: Formulations and Combination Strategies**
Beyond novel targets, improving existing drugs is also an important direction. For example, low-dose oral minoxidil (0.5–2.5 mg per day) can reduce local irritation and improve compliance; topical finasteride sprays (e.g., P-3074) have shown efficacy comparable to oral finasteride in phase III trials without systemic side effects. Combination therapy (e.g., finasteride plus minoxidil, or combined with low-level laser therapy) is already widely used in clinical practice, but data on combinations involving different new drugs remain lacking.
**Summary and Rational Outlook**
At present, no novel AGA drug has completed large-scale phase III randomized controlled trials and received approval from major regulatory agencies. The most promising candidates, such as clascoterone and GT-20029, are still in mid-to-late clinical stages, with results expected within 3–5 years. Patients should be wary of any marketing claims of “cure” or “hair regrowth in three days,” as hair loss treatment is essentially a long-term process of maintaining existing hair follicles. For novel therapies, it is advisable to monitor registered clinical trials (e.g., on ClinicalTrials.gov) and consult a dermatologist.
*For reference only, not medical advice.*